PFSCF News Alert Prometic Life Scienc (PFSCF) 1.6500 02/15/2015
Post# of 64074
Posted On: 02/15/2015 9:10:28 AM
Prometic Life Scienc (PFSCF) 1.6500 $PFSCF
ProMetic Receives $11.4 Million Purchase Order from Multinational Client
Marketwired - Thu Feb 12, 6:03AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
announced today that it has received an $11.4 million purchase order for the supply of affinity resin from an existing client, a global leader in the biotherapeutics industry.
PLI.TO: 2.06 (+0.15)
ProMetic's PBI-4050 Cleared to Commence Clinical Trials in Patients With Idiopathic Pulmonary Fibrosis
Marketwired - Wed Feb 04, 6:02AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" reported today that its orally active anti-fibrotic lead drug candidate, PBI-4050, has been approved to commence the clinical trial in patients suffering from idiopathic pulmonary fibrosis ("IPF" , following the CTA clearance by Health Canada.
PLI.TO: 2.06 (+0.15)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
ProMetic's PBI-4050 Cleared to Commence Clinical Trials in Patients with Metabolic Syndrome and Associated Type 2 Diabetes
Marketwired - Mon Jan 26, 5:31AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" reported today that its orally active lead drug candidate, PBI-4050, has been approved to commence the clinical trial in patients suffering from metabolic syndrome and resulting Type 2 diabetes, following the CTA clearance by Health Canada. Metabolic syndrome is a major risk factor for cardiovascular disease and for Type 2 diabetes, and consists of the constellation of central (truncal) obesity, high blood triglycerides, low HDL ("good" cholesterol, elevated blood pressure, and elevated blood glucose.
PLI.TO: 2.06 (+0.15)
ProMetic Provides Q4 2014 Clinical Development and Commercial Milestones Update
Marketwired - Tue Jan 06, 5:31AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" provided today an update on its clinical development and commercial milestones scheduled for completion in Q4 2014.
PLI.TO: 2.06 (+0.15)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 43.76 (+0.61), RPTP: 9.05 (-0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), TBRA: ()
ProMetic Enters Into Strategic Alliance with GENERIUM Pharmaceuticals
Marketwired - Mon Dec 22, 8:19AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) -
PLI.TO: 2.06 (+0.15)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 101.90 (+1.10), ICPT: 209.12 (+7.12), TBRA: (), CELGZ: 3.17 (-0.04)
ProMetic Announces the Exercise of the Over-Allotment Option Under its Bought Deal Offering of Common Shares
Marketwired - Fri Dec 12, 10:38AM CST
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation" is pleased to announce that it has received a notice of exercise of the over-allotment option (the "Over-Allotment Option" to acquire an additional 1,980,000 common shares (the "Over-Allotment Shares" at a price of $1.90 per Over-Allotment Share, for gross proceeds of $3,762,000, from the syndicate of underwriters led by Canaccord Genuity Corp., and which includes Paradigm Capital Inc., RBC Capital Markets and Beacon Securities Limited (the "Underwriters" . The Underwriters were granted the Over-Allotment Option in connection with the previously announced bought deal offering of common shares of the Corporation, which closed on December 9, 2014. Closing of the Over-Allotment Option is expected to occur on or about December 15, 2014.
PLI.TO: 2.06 (+0.15)
ProMetic Announces Closing of Bought Deal Offering of Common Shares
Marketwired - Tue Dec 09, 7:46AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" is pleased to announce that it has closed its previously announced bought deal public offering of common shares in the capital of the Corporation (the "Offering" through a syndicate of underwriters led by Canaccord Genuity Corp., and which included Paradigm Capital Inc., RBC Capital Markets and Beacon Securities Limited (collectively, the "Underwriters" . ProMetic issued 13,200,000 common shares of the Corporation in connection with the Offering at a price of $1.90 per share for aggregate gross proceeds of $25,080,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission of 5.5% of the gross proceeds of the Offering.
PLI.TO: 2.06 (+0.15)
ProMetic's PBI-4050 to Target Patients With the Metabolic Syndrome and Associated Type 2 Diabetes
Marketwired - Thu Dec 04, 6:02AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" announced today that it is pursuing a clinical program designed to evaluate the benefit of PBI-4050 in patients affected by the metabolic syndrome and resulting Type 2 diabetes. The metabolic syndrome is a major risk factor for cardiovascular disease and for Type 2 diabetes, and consists of the constellation of central (truncal) obesity, high blood triglycerides, low HDL ("good" cholesterol, elevated blood pressure, and elevated blood glucose. Obesity is believed to cause a chronic inflammatory state, which leads to insulin resistance and so may in turn result in cardiovascular disease and/or Type 2 diabetes. Given the global epidemic of obesity, both in the developed and developing world, the metabolic syndrome and its consequences present a devastating public health problem.
PLI.TO: 2.06 (+0.15)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), ASPX: 65.76 (+2.76), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
ProMetic Receives $11.4 Million Purchase Order from Multinational Client
Marketwired - Thu Feb 12, 6:03AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
announced today that it has received an $11.4 million purchase order for the supply of affinity resin from an existing client, a global leader in the biotherapeutics industry. PLI.TO: 2.06 (+0.15)
ProMetic's PBI-4050 Cleared to Commence Clinical Trials in Patients With Idiopathic Pulmonary Fibrosis
Marketwired - Wed Feb 04, 6:02AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
reported today that its orally active anti-fibrotic lead drug candidate, PBI-4050, has been approved to commence the clinical trial in patients suffering from idiopathic pulmonary fibrosis ("IPF" , following the CTA clearance by Health Canada. PLI.TO: 2.06 (+0.15)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
ProMetic's PBI-4050 Cleared to Commence Clinical Trials in Patients with Metabolic Syndrome and Associated Type 2 Diabetes
Marketwired - Mon Jan 26, 5:31AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
reported today that its orally active lead drug candidate, PBI-4050, has been approved to commence the clinical trial in patients suffering from metabolic syndrome and resulting Type 2 diabetes, following the CTA clearance by Health Canada. Metabolic syndrome is a major risk factor for cardiovascular disease and for Type 2 diabetes, and consists of the constellation of central (truncal) obesity, high blood triglycerides, low HDL ("good" cholesterol, elevated blood pressure, and elevated blood glucose. PLI.TO: 2.06 (+0.15)
ProMetic Provides Q4 2014 Clinical Development and Commercial Milestones Update
Marketwired - Tue Jan 06, 5:31AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
provided today an update on its clinical development and commercial milestones scheduled for completion in Q4 2014. PLI.TO: 2.06 (+0.15)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 43.76 (+0.61), RPTP: 9.05 (-0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), TBRA: ()
ProMetic Enters Into Strategic Alliance with GENERIUM Pharmaceuticals
Marketwired - Mon Dec 22, 8:19AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) -
PLI.TO: 2.06 (+0.15)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 101.90 (+1.10), ICPT: 209.12 (+7.12), TBRA: (), CELGZ: 3.17 (-0.04)
ProMetic Announces the Exercise of the Over-Allotment Option Under its Bought Deal Offering of Common Shares
Marketwired - Fri Dec 12, 10:38AM CST
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation"
is pleased to announce that it has received a notice of exercise of the over-allotment option (the "Over-Allotment Option" to acquire an additional 1,980,000 common shares (the "Over-Allotment Shares" at a price of $1.90 per Over-Allotment Share, for gross proceeds of $3,762,000, from the syndicate of underwriters led by Canaccord Genuity Corp., and which includes Paradigm Capital Inc., RBC Capital Markets and Beacon Securities Limited (the "Underwriters" . The Underwriters were granted the Over-Allotment Option in connection with the previously announced bought deal offering of common shares of the Corporation, which closed on December 9, 2014. Closing of the Over-Allotment Option is expected to occur on or about December 15, 2014. PLI.TO: 2.06 (+0.15)
ProMetic Announces Closing of Bought Deal Offering of Common Shares
Marketwired - Tue Dec 09, 7:46AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
is pleased to announce that it has closed its previously announced bought deal public offering of common shares in the capital of the Corporation (the "Offering" through a syndicate of underwriters led by Canaccord Genuity Corp., and which included Paradigm Capital Inc., RBC Capital Markets and Beacon Securities Limited (collectively, the "Underwriters" . ProMetic issued 13,200,000 common shares of the Corporation in connection with the Offering at a price of $1.90 per share for aggregate gross proceeds of $25,080,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission of 5.5% of the gross proceeds of the Offering. PLI.TO: 2.06 (+0.15)
ProMetic's PBI-4050 to Target Patients With the Metabolic Syndrome and Associated Type 2 Diabetes
Marketwired - Thu Dec 04, 6:02AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
announced today that it is pursuing a clinical program designed to evaluate the benefit of PBI-4050 in patients affected by the metabolic syndrome and resulting Type 2 diabetes. The metabolic syndrome is a major risk factor for cardiovascular disease and for Type 2 diabetes, and consists of the constellation of central (truncal) obesity, high blood triglycerides, low HDL ("good" cholesterol, elevated blood pressure, and elevated blood glucose. Obesity is believed to cause a chronic inflammatory state, which leads to insulin resistance and so may in turn result in cardiovascular disease and/or Type 2 diabetes. Given the global epidemic of obesity, both in the developed and developing world, the metabolic syndrome and its consequences present a devastating public health problem. PLI.TO: 2.06 (+0.15)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), ASPX: 65.76 (+2.76), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
(0)
(0)Scroll down for more posts ▼